BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Perampanel: Phase III data

Researchers at New York University's Comprehensive Epilepsy Center and colleagues reported data from an international Phase III trial of perampanel as an adjunctive therapy for partial seizures in patients with epilepsy. In the full intent-to-treat (ITT) population (n=387), which consisted of all treated patients with any post-baseline seizure data, 8 and 12 mg perampanel met the primary endpoint of significantly reducing median seizure frequency per 28 days during the 19-week double-blind treatment period (6-week titration phase followed by a 13-week maintenance period) vs. placebo (26.3%...

Read the full 403 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >